MedPath

TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I)

Not Applicable
Terminated
Conditions
Overactive Bladder Syndrome
Interventions
Device: TTNS Sham
Device: TTNS
Registration Number
NCT04256876
Lead Sponsor
University Hospital, Ghent
Brief Summary

Part I of the TaPaS trial forms part of a twofold clinical RCT:

Part 1) A prospective RCT comparing the efficacy of transcutaneous tibial nerve stimulation (TTNS) with TTNS sham therapy for children with idiopathic overactive bladder on clinical and patient reported outcomes (PROMS).

Part 2) A prospective RCT comparing TTNS versus Percutaneous tibial nerve stimulation (PTNS) on clinical outcomes and PROMS.

Detailed Description

Non invasive neuromodulation therapy for children with the overactive bladder syndrome is a highly under investigated topic in medical literature.

Only 2 studies ( Patidar et al. and Boudaouid et al.) investigated the use of tibial nerve stimulation with adhesive electrodes.

1) In the first trial the superiority of TTNS vs.Sham therapy for the therapeutic management of children with OAB naive to any pharmacological treatment will be examined.

Clinical outcomes will be assessed by the use of daytime and nighttime bladder diaries.

Assessment of outcomes at baseline, after 6 weeks and 12 weeks of treatment, and investigation of mean time to partial or complete relapse following 6 weeks observation.

After a wash-out period of 6 weeks, patients from the part I Sham group will be able to be included for TaPaS part II.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Children between 5 and 12 years old, clinically diagnosed with the idiopathic overactive bladder syndrome with urinary incontinence (daytime and/or nighttime)
  • Untreated, except from urotherapy.
Exclusion Criteria
  • Enuresis nocturna due to nocturnal polyuria
  • Dysfunctional voiding
  • Neurogenic bladder
  • Psychiatric disorders, behavioural disturbances or mental disabilities
  • Treated before with pharmacotherapy or invasive therapies for OAB
  • Children with parents unable to record reliably micturition diaries.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TTNS sham interventionTTNS ShamChildren treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld. Home therapy: Daily stimulation during 60 minutes.
Active TTNSTTNSChildren treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
Primary Outcome Measures
NameTimeMethod
Mean voided volume per void12 weeks

Difference in mean voided volume per void in percentage

Secondary Outcome Measures
NameTimeMethod
Maximum voided volume (ml)12 weeks

Maximal voided volume per void ( ml) .

Number of urgency incontinence episodes / 24 h.12 weeks

Reduction in number of incontinence episodes per 24 hour

Daytime voiding frequency12 weeks

Mean voiding frequency per day

Satisfaction on urinary symptoms reported by parents12 weeks

Subjective satisfaction reported by the parents - on a 7 point likert scale- "How satisfied of dissatisfied would you be if the bladder symptoms of your child would persist like this?

Time to recurrenceAt 12 weeks of treatment + at 6 weeks of observational period without treatment.

Time to complete or partial relapse to baseline symptoms after 12 weeks of treatment during the observational period of 6 weeks.

Trial Locations

Locations (1)

University Hospital Ghent

🇧🇪

Gent, East-Flanders, Belgium

© Copyright 2025. All Rights Reserved by MedPath